ESH 2017 | Therapeutics targeting splicing in hematological malignancies

Omar Abdel-Wahab

Currently, the majority of therapeutics that target splicing mutations in hematological malignancies are in the early or pre-clinical phases. In this video, Omar Abdel-Wahab, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, discusses one such exciting trial, NCT02841540. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH).

Share this video  
Similar topics
Related videos
Venetoclax-resistance conferring mutation in CLL identified
Piers Blombery
Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
An exciting era for CAR T-cell therapy
Mohamad Mohty
Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno
JCAR017 for relapsed/refractory CLL
Tanya Siddiqi
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes
H3B-8800
ESH 2017
Interview
10th October 2017
More from Omar Abdel-Wahab
The importance of collaboration in AML research
The spliceosome mutations that can cause hematological malignancies
Neomorphic mutations driving hematological cancers
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals